Iranian Society of Gynecology Oncology


1 Gynecology Oncology Department, Medicine Faculty, Tehran University of Medical Sciences, Tehran, Iran

2 Obstetrics & Gynecology Oncology Department, Medicine Faculty, Sabzevar University of Medical Sciences, Sabzevar, Iran

3 Research Center for Health Sciences” and “Epidemiology Department, Health & Nutrition Faculty”, Shiraz University of Medical Sciences, Shiraz, Iran


Aims: Ovarian cancer is the 4th cause of women’s mortality occurring due to cancer. Malignant germ cell tumors (GCTs) account for 5% of malignant ovarian tumors and 70% of ovarian tumors in women between the ages of 10-30 years old. The aim of the present study was to detect the frequency of malignant ovarian germ cell tumor and distribution of demographic features in the most crowded gynecology oncology clinic.
Materials and Methods: This cohort descriptive-analytical study was conducted on cases with malignant ovarian tumor managed in Vali-Asr hospital, Tehran, Iran, from 2001 to 2018 (n=1540). The malignant germ cell tumors cases were extracted (n=128) and evaluated in point of epidemiologic and demographic data via the software SPSS 24.
Findings: 128 patients (8.3%) had GCTs. The average age was 23.88±7.85 years. 79.7% lived in the city, 76.6% had medium economic status and 53.6% had normal body mass index. Premature puberty was revealed in one person. Karyotype XY was detected in 5 persons. About 70.3% of the patients had no parity. In parous women, the highest percentage was related to a childbirth (55.0%). A history of infertility was detected at 6.1%. In 10 patients, the tumor was detected during pregnancy.
Conclusion: The highest frequency is related to the early young women with no considerable association with socioeconomic and weight status. It is possible that parity would be a protective factor for this tumor. In the case of adnexal mass during pregnancy, Malignant Germ cell tumors should be rolled out.


  1. Lukanova A, Kaaks R. Endogenous hormones and ovarian cancer: Epidemiology and current hypotheses. Cancer Epidemiol Biomarkers Prev. 2005;14(1):98-107.
  2. Khatri R. Clinicopathological analysis of ovarian tumours at birendra military hospital. Med J Shree Birendra Hosp. 2011;10(1):26-31. [DOI:10.3126/mjsbh.v10i1.6446]
  3. Jha R, Karki S. Histological pattern of ovarian tumors and their age distribution. Nepal Med Coll J. 2008;10(2):81-5.
  4. Jemal A, Thomas A, Murray T, Thun M. Cancer statistics, 2002. CA Cancer J Clin. 2002;52(1):23-47. [DOI:10.3322/canjclin.52.1.23] [PMID]
  5. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127(12):2893-917. [DOI:10.1002/ijc.25516] [PMID]
  6. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359-86. [DOI:10.1002/ijc.29210] [PMID]
  7. Boffetta P, Boccia S, La Vecchia C. A quick guide to cancer epidemiology. Heidelberg: Springer Science & Business Media; 2014. [DOI:10.1007/978-3-319-05068-3]
  8. La Vecchia C. Ovarian cancer: Epidemiology and risk factors. Eur J Cancer Prev. 2017;26(1):55-62. [DOI:10.1097/CEJ.0000000000000217] [PMID]
  9. Li CC, Hirokawa M, Qian Z, Fujii Y, Ino H, Wakatsuki S, et al. Morules with optically clear nuclei in ovarian borderline endometrioid tumor. Apmis. 2002;110(11):783-8. [DOI:10.1034/j.1600-0463.2002.1101103.x] [PMID]
  10. Agah J, Karimzadeh S, Moharrer Ahmadi F. Misdiagnosis of a giant uterine leiomyosarcoma: Clinic and image challenges. Case Rep Oncol Med. 2017;2017:3568328. [DOI:10.1155/2017/3568328] [PMID]
  11. Agah J, Jafarzadeh Esfehani R, Kamalimanesh B, Fattahi Abdizadeh M, Jalilian AR. Mismanagement of a huge ovarian serous cystadenoma in a young girl, a case report. J Midwifery Reprod Health. 2015;3(1):315-7.
  12. Tewari K, Cappuccini F, Disaia PJ, Berman ML, Manetta A, Kohler MF. Malignant germ cell tumors of the ovary. Obstet Gynecol. 2000;95(1):128-33. [DOI:10.1016/S0029-7844(99)00470-6]
  13. Smith HO, Berwick M, Verschraegen CF, Wiggins C, Lansing L, Muller CY, et al. Incidence and survival rates for female malignant germ cell tumors. Obstet Gynecol. 2006;107(5):1075-85. [DOI:10.1097/01.AOG.0000216004.22588.ce] [PMID]
  14. Dalmau J, Gleichman AJ, Hughes EG, Rossi JE, Peng X, Lai M, et al. Anti-NMDA-receptor encephalitis: Case series and analysis of the effects of antibodies. Lancet Neurol. 2008;7(12):1091-8. [DOI:10.1016/S1474-4422(08)70224-2]
  15. Tongsong T, Luewan S, Phadungkiatwattana P, Neeyalavira V, Wanapirak C, Khunamornpong S, et al. Pattern recognition using transabdominal ultrasound to diagnose ovarian mature cystic teratoma. Int J Gynaecol Obstet. 2008;103(2):99-104. [DOI:10.1016/j.ijgo.2008.06.002] [PMID]
  16. Gershenson DM. Update on malignant ovarian germ cell tumors. Cancer. 1993;71(S4):1581-90. [DOI:10.1002/cncr.2820710425] [PMID]
  17. Colombo N, Peiretti M, Garbi A, Carinelli S, Marini C, Sessa C, et al. Non-epithelial ovarian cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2012;23 Suppl 7:vii20-6. [DOI:10.1093/annonc/mds223] [PMID]
  18. Litchfield K, Levy M, Orlando G, Loveday C, Law PJ, Migliorini G, et al. Identification of 19 new risk loci and potential regulatory mechanisms influencing susceptibility to testicular germ cell tumor. Nat Genet. 2017;49(7):1133-40. [DOI:10.1038/ng.3896] [PMID]
  19. Sanfrancesco JM, Trevino KE, Xu H, Ulbright TM, Idrees MT. The significance of spermatic cord involvement by testicular germ cell tumors: Should we be staging discontinuous invasion from involved lymphovascular spaces differently from direct extension?. Am J Surg Pathol. 2018;42(3):306-11. [DOI:10.1097/PAS.0000000000001008] [PMID]
  20. Awuah SG, Riddell IA, Lippard SJ. Repair shielding of platinum-DNA lesions in testicular germ cell tumors by high-mobility group box protein 4 imparts cisplatin hypersensitivity. Proc Natl Acad Sci U S A. 2017;114(5):950-5. [DOI:10.1073/pnas.1615327114] [PMID]
  21. Pectasides D, Pectasides E, Kassanos D. Germ cell tumors of the ovary. Cancer Treat Rev. 2008;34(5):427-41. [DOI:10.1016/j.ctrv.2008.02.002] [PMID]
  22. Gershenson DM. Management of ovarian germ cell tumors. J Clin Oncol. 2007;25(20):2938-43. [DOI:10.1200/JCO.2007.10.8738] [PMID]
  23. Arab M, Khayamzadeh M, Hashemi M, Hosseini M, Tabatabaeefar M, Anbiaee R, et al. Crude and age-specific incidence rate patterns for histopathologic subtypes of ovarian cancer in Iran. Arch Iran Med. 2010;13(3):203-8.
  24. Arab M, Khayamzadeh M, Tehranian A, Tabatabaeefar M, Hosseini M, Anbiaee R, et al. Incidence rate of ovarian cancer in Iran in comparison with developed countries. Indian J Cancer. 2010;47(3):322-7. [DOI:10.4103/0019-509X.64721] [PMID]
  25. Robboy SJ, Shaco-Levy R, Peng RY, Snyder MJ, Donahue J, Bentley RC, et al. Malignant struma ovarii: An analysis of 88 cases, including 27 with extraovarian spread. Int J Gynecol Pathol. 2009;28(5):405-22. [DOI:10.1097/PGP.0b013e3181a27777] [PMID]
  26. Shaco-Levy R, Bean SM, Bentley RC, Robboy SJ. Natural history of biologically malignant struma ovarii: Analysis of 27 cases with extraovarian spread. Int J Gynecol Pathol. 2010;29(3):212-27. [DOI:10.1097/PGP.0b013e3181bfb133] [PMID]
  27. Lee-Jones L. Ovary: Germ cell tumors. Atlas Genet Cytogenet Oncol Haematol. 2003;7(4):278-84.
  28. Quirk JT, Natarajan N, Mettlin CJ. Age-specific ovarian cancer incidence rate patterns in the United States. Gynecol Oncol. 2005;99(1):248-50. [DOI:10.1016/j.ygyno.2005.06.052] [PMID]
  29. Leitzmann MF, Koebnick C, Danforth KN, Brinton LA, Moore SC, Hollenbeck AR, et al. Body mass index and risk of ovarian cancer. Cancer. 2009;115(4):812-22. [DOI:10.1002/cncr.24086] [PMID]
  30. Yosefi Z, Homaei F. Evaluation of risk factors and prognostic factors of ovarian cancer. J Med Counc Iran. 2006;24(3):279-88. [Persian]
  31. Bakri YN, Ezzat A, Akhtar M, Dohami H, Zahrani A. Malignant germ cell tumors of the ovary: Pregnancy considerations. Eur J Obstet Gynecol Reprod Biol. 2000;90(1):87-91. [DOI:10.1016/S0301-2115(99)00213-4]
  32. Kamalimanesh B, Jafarzadeh Esfehani R, Agah J. Papillary serous cystadenoma of ovary: A huge ovarian cyst complicating the pregnancy. J Cases Obstet Gynecol. 2016;3(4):121-4.
  33. Stewart LM, Spilsbury K, Jordan S, Stewart C, Holman CDJ, Powell A, et al. Risk of high-grade serous ovarian cancer associated with pelvic inflammatory disease, parity and breast cancer. Cancer Epidemiol. 2018;55:110-6. [DOI:10.1016/j.canep.2018.05.011] [PMID]
  34. Dobashi M, Isonishi S, Morikawa A, Takahashi K, Ueda K, Umezawa S, et al. Ovarian cancer complicated by pregnancy: Analysis of 10 cases. Oncol Lett. 2012;3(3):577-80. [DOI:10.3892/ol.2011.545] [PMID]
  35. Cox S, Werner C, Hoffman B, Cunningham F. Williams Obstetrics 22nd Edition Study Guide. New York City: McGraw-Hill Professional; 2005.
  36. Parsanezhad ME, Jahromi BN, Zare N, Keramati P, Khalili A, Parsa Nezhad M. Epidemiology and etiology of infertility in Iran, systematic review and meta-analysis. J Womens Health Issues Care. 2013;2(6). [DOI:10.4172/2325-9795.1000121]
  37. Reid BM, Permuth JB, Sellers TA. Epidemiology of ovarian cancer: A review. Cancer Biol Med. 2017;14(1):9-32. [DOI:10.20892/j.issn.2095-3941.2016.0084] [PMID]
  38. Berek JS, Natarajan S. Ovarian and fallopian tube cancer. In: Berek JS, editor. Berek & Novak's gynecology. 14th Edition. Philadelphia: Lippincott Williams & Wilkins; 2007. pp. 1457-549.
  39. Copeland LJ. Epithelial ovarian cancer. In: Di Saia P, Creasman W. Clinical gynecologic oncology. 7th Edition. Maryland Heights: Mosby; 2007. pp. 313-67. [DOI:10.1016/B978-032303978-9.50014-9]
  40. Webb PM, Jordan SJ. Epidemiology of epithelial ovarian cancer. Best Pract Res Clin Obstet Gynaecol. 2017;41:3-14. [DOI:10.1016/j.bpobgyn.2016.08.006] [PMID]